title: Impact of aliskiren on some hemostatic parameters in experimental arterial thrombosis in rats.
abstract: BACKGROUND
  Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. A number of studies show a link between aliskiren and intravascular thrombosis.
  
  
  METHODS
  The goal of the present study was to investigate the impact of aliskiren on arterial thrombosis in normotensive and renovascular hypertensive rats. The contribution of each coagulation and fibrinolytic parameters in the mode of aliskiren action was determined. Six weeks after clipping of the left renal artery rats developed hypertension which was confirmed by the "tail cuff" method. Animals were treated with aliskiren (10, 30 and 100mg/kg/day) per os for 10 days. Arterial thrombosis was induced by electrical stimulation of the common carotid artery.
  
  
  RESULTS
  It was found that aliskiren in a dose-dependent manner decreased weight of the arterial thrombus in normotensive and hypertensive rats. It has been shown that this result was not associated with the effects on blood pressure, TF, PT, APTT, fibrinogen and hematological parameters. It was found that aliskiren caused increase of t-PA activity and decrease of its inhibitor activity.
  
  
  CONCLUSIONS
  The presented results indicate that aliskiren inhibits hemostasis in the arterial thrombosis in rats. The antithrombotic effect is related with improvement of the fibrinolytic balance, and also depends on antiplatelet action.
authors.affiliation: Department of Clinical Pharmacy, Medical University of Bialystok, Białystok, Poland; Department of Pharmacodynamics, Medical University of Bialystok, Białystok, Poland. Electronic address: justyna.hermanowicz@umb.edu.pl.
authors.forename: Justyna Magdalena
authors.initials: JM
authors.lastname: Hermanowicz
authors.affiliation: Department of Orthodontics, Medical University of Bialystok, Białystok, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Buczko
authors.affiliation: Department of Monitored Pharmacotherapy, Medical University of Bialystok, Białystok, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Tankiewicz-Kwedlo
authors.affiliation: Department of Pediatric Surgery, Medical University of Bialystok, Białystok, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Hermanowicz
authors.affiliation: Higher State Vocational School, Institute of Health Care, Suwałki, Poland.
authors.forename: Wlodzimierz
authors.initials: W
authors.lastname: Buczko
mesh_terms: D000577:Amides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D005650:Fumarates / Q000494:pharmacology* / Q000627:therapeutic use*; D006487:Hemostasis / Q000187:drug effects*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D013927:Thrombosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D001779:Blood Coagulation Factors; D005650:Fumarates; D017395:Plasminogen Activator Inhibitor 1; C446481:aliskiren; D010959:Tissue Plasminogen Activator
keywords: Aliskiren; Arterial thrombosis; Hemostatic parameters; Rats